<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s40545-019-0182-1</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">40545</journal-id><journal-title-group><journal-title>Journal of Pharmaceutical Policy and Practice</journal-title><abbrev-journal-title abbrev-type="publisher">J of Pharm Policy and Pract</abbrev-journal-title></journal-title-group><issn pub-type="epub">2052-3211</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s40545-019-0182-1</article-id><article-id pub-id-type="manuscript">182</article-id><article-id pub-id-type="doi">10.1186/s40545-019-0182-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Need to improve availability of “access” group antibiotics and reduce the use of “watch” group antibiotics in India for optimum use of antibiotics to contain antimicrobial resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Gandra</surname><given-names>Sumanth</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au2"><name><surname>Kotwani</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="corresp" rid="IDs4054501901821_cor2">b</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution content-type="org-division">Department of Medicine</institution><institution content-type="org-name">Washington University School of Medicine</institution></institution-wrap><addr-line content-type="city">Saint Louis</addr-line><addr-line content-type="state">MO</addr-line><country country="US">USA</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2109 4999</institution-id><institution-id institution-id-type="GRID">grid.8195.5</institution-id><institution content-type="org-division">Department of Pharmacology</institution><institution content-type="org-name">V. P. Chest Institute, University of Delhi</institution></institution-wrap><addr-line content-type="postcode">110007</addr-line><addr-line content-type="city">Delhi</addr-line><country country="IN">India</country></aff></contrib-group><author-notes><corresp id="IDs4054501901821_cor2"><label>b</label><email>anitakotwani@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>7</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>12</volume><issue seq="20">1</issue><elocation-id>20</elocation-id><history><date date-type="registration"><day>16</day><month>5</month><year>2019</year></date><date date-type="received"><day>1</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2019</year></date><date date-type="online"><day>17</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s). 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="url">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>5</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>16</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/40545_2019_Article_182.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Pharmacy</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Pharmacy</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Pharmaceutical Sciences/Technology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Pharmacology/Toxicology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Drug Safety and Pharmacovigilance</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Pharmacoeconomics and Health Outcomes</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="AuthorContribution"><p>Sumanth Gandra and Anita Kotwani contributed equally to this work.</p></notes></front><body><p id="Par11">Antimicrobial resistance (AMR) is a growing public health threat and one of its biggest drivers is inappropriate use of antibiotics [<xref ref-type="bibr" rid="CR1">1</xref>]. To optimize the use of antimicrobials, the World Health Organization (WHO) in 2017 updated the Essential Medicine List (EML) and categorized the antibiotics into three groups- Access, Watch and Reserve (AWaRe) [<xref ref-type="bibr" rid="CR2">2</xref>]. The Access group antibiotics are the first and second choices for empirical treatment of 21 common clinical syndromes. First choices are narrow spectrum agents whereas second choice are broad spectrum agents with higher resistance potential. Antibiotics such as amoxicillin/ampicillin, benzathine penicillin, trimethoprim-sulfamethoxazole, amoxicillin-clavulanic acid, cloxacillin are first choice agents. Watch group includes antibiotics with high resistance potential when compared with the Access group and includes antibiotics such as third generation cephalosporins, fluoroquinolones and carbapenems. The Reserve group includes antibiotics of last-resort like polymyxins, fourth and fifth generation cephalosporins. WHO recommends that Access group of antibiotics should be widely available and at an affordable cost and minimize the use of other two groups of antibiotics. A recent report analyzed antibiotic sales data in India between 2007 and 2012 which showed that the consumption of Watch group and Reserve group antibiotics are increasing rapidly when compared to Access group of antibiotics [<xref ref-type="bibr" rid="CR3">3</xref>]. Here we discuss the consumption patterns of certain antibiotics in Access group and Watch group and the reasons for their consumption patterns.</p><p id="Par12">Human antibiotic consumption in India is among the highest in the world [<xref ref-type="bibr" rid="CR4">4</xref>]. Antibiotic consumption in India increased from 3.2 billion DDDs (defined daily doses) in 2000 to 6.5 billion DDDs in 2015 [<xref ref-type="bibr" rid="CR4">4</xref>]. Although per-capita consumption of antibiotics in India is low when compared to several other countries [<xref ref-type="bibr" rid="CR4">4</xref>], the proportion of broad-spectrum antibiotics (Watch group and Reserve group) consumption is high as evident in analysis of pediatric antibiotic sales data in 70 countries [<xref ref-type="bibr" rid="CR5">5</xref>]. The use of third generation cephalosporins which belongs to Watch group is increasing rapidly in India [<xref ref-type="bibr" rid="CR6">6</xref>]. In contrast to the rapid rise in the consumption of third generation cephalosporins between 2000 and 2015, the consumption of fluoroquinolones (Watch group antibiotics) is decreasing whereas penicillins (Access group antibiotics) consumption remained constant [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par13">The combination of broad-spectrum activity, availability in oral and parenteral formulations, convenient dosing and minimal adverse effects make second and third generation cephalosporins an ideal choice for prescribers in both adults and children. Although, second and third generation cephalosporins offer several advantages, their use increases the risk of colonization with extended spectrum beta-lactamase (ESBLs) producing Enterobacteriaceae (e.g.: <italic>E. coli</italic>) that are part of human normal intestinal flora [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The high prevalence of third generation cephalosporin resistant Enterobacteriaceae among clinical isolates obtained from both children and adults in India [<xref ref-type="bibr" rid="CR9">9</xref>] correlates well with the increasing consumption of third generation cephalosporins due to selection pressure. In a national scale study 2014, using a large private diagnostic laboratory network data, approximately 80% of the <italic>E.coli</italic> isolates obtained from blood cultures were resistant to third generation cephalosporins [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par14">The increasing use of second and third generation cephalosporins belonging to Watch group could be attributed to combination of factors such as changing prescribing practices, increasing antimicrobial resistance to other antibiotic classes and lack of availability of first-line penicillin antibiotics belonging to Access group.</p><sec id="Sec1"><title>Changing prescribing practices</title><p id="Par15">In a 2004 study assessing antibiotic consumption in private retail pharmacies in Delhi showed that fluoroquinolones were most commonly consumed antibiotics followed by penicillins and cephalosporins [<xref ref-type="bibr" rid="CR10">10</xref>]. Consumption of cephalosporins was about 39% less than fluoroquinolone. A repeat study in 2007 in the same areas in private retail pharmacies showed equal consumption of cephalosporins and fluoroquinolones [<xref ref-type="bibr" rid="CR11">11</xref>]. Three most commonly prescribed cephalosporins were cefuroxime, cefixime and combination of cefixime and clavulanic acid all of which belonged to Watch group [<xref ref-type="bibr" rid="CR11">11</xref>].Penicillins are recommended as the first line antibiotics for treatment of respiratory tract infections [<xref ref-type="bibr" rid="CR12">12</xref>]. However, recent trends indicate that penicillins are increasingly substituted by second and third generation cephalosporins for treatment of respiratory tract infections in both outpatient [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] and inpatient settings [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In a study between December 2007 and November 2008 which conducted exit interviews of patients with upper respiratory tract infections showed that in private clinics, cephalosporins were prescribed to 39% of patients followed by fluoroquinolone (24%), penicillins (19%) and macrolides (11%) [<xref ref-type="bibr" rid="CR13">13</xref>]. However, in public clinics, the main class of antibiotics prescribed were penicillins (31%), followed by macrolides (25%), fluoroquinolones (20%) and cephalosporins (10%). In a 2014 qualitative study involving focus-group discussions and face-to-face interviews with doctors and pharmacists to study the behavior and perception about antibiotic use for acute upper respiratory tract infections (URTIs) and diarrhea in children in New Delhi indicated that some General Practitioners use cefixime and cefpodoxime for URTIs [<xref ref-type="bibr" rid="CR14">14</xref>]. In a retrospective five-year study between 2007 and 2012 among hospitalized patients with community acquired pneumonia showed that cephalosporin prescriptions significantly increased whereas penicillin prescriptions significantly decreased over the study period [<xref ref-type="bibr" rid="CR15">15</xref>]. Among the total antibiotic prescriptions, cephalosporin consumption increased from 16% in 2007 to 27% in 2012, whereas penicillins consumption decreased from 30% in 2007 to 16% in 2012 [<xref ref-type="bibr" rid="CR15">15</xref>]. In a recent multicenter study involving six pediatric hospitals in 2016, third generation cephalosporins were the most commonly prescribed antibiotics for lower respiratory tract infections (LRTIs) and accounted for 37% of the prescriptions for LRTIs among hospitalized children [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par16">Changing prescribing practices among healthcare providers could be due to multiple factors and one such factor could be the influence of marketing and promotion practices of drug manufactures. Although third generation cephalosporins belonging to Watch group are increasingly used for treatment of respiratory tract infections, studies indicate that penicillins belonging to Access group are still active against the common bacterial pathogens causing respiratory tract infections. In a recent study examining resistance rates of pathogens isolated from community acquired pneumonia patients in India between 2012 and 2014, showed high susceptibility to amoxicillin/ampicillin and amoxicillin-clavulanic acid [<xref ref-type="bibr" rid="CR17">17</xref>]. In this study, the susceptibility rates of <italic>Streptococcus pneumoniae</italic> and <italic>Streptococcus pyogenes</italic> for amoxicillin were 92 and 100%, respectively. For <italic>Hemophilus influenzae</italic>, ampicillin susceptibility was 91% and amoxicillin/clavulanic acid was 97%, respectively [<xref ref-type="bibr" rid="CR17">17</xref>]. These findings reassure prescribers to follow the published treatment guidelines by National Center for Disease Control and INDIACLEN Taskforce on Pneumonia, which recommend use of Access group of antibiotics (amoxicillin, amoxicillin-clavulanic acid and ampicillin-gentamicin (in young children)) for community acquired respiratory tract infections as empiric treatment choice in both outpatient and inpatient settings [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Third generation cephalosporins belonging to Watch group should be reserved for very sick patients or patients admitted to intensive care units or when there is a clinical deterioration on first line agents belonging to Access group.</p></sec><sec id="Sec2"><title>Increasing antimicrobial resistance to fluoroquinolones</title><p id="Par17">Quinolones belonging to Watch group have been the main stay of treatment for enteric fever and bacterial dysentery which account for a huge burden of infections in India. Several recent studies reported increasing quinolone resistance among bacteria causing these infections. In a national scale retrospective study on antimicrobial susceptibility of various bacterial pathogens between 2008 and 2014, <italic>Salmonella</italic> Typhi resistance to nalidixic acid was 98% [<xref ref-type="bibr" rid="CR9">9</xref>]. Similarly, ciprofloxacin resistance among <italic>S</italic>. Typhi was 69% in 2014 as per Indian Council of Medical Research (ICMR) AMR surveillance network hospitals [<xref ref-type="bibr" rid="CR20">20</xref>]. Quinolone resistance among <italic>Shigella spp</italic>. and <italic>Campylobacter spp</italic>. causing bacterial dysentery is also increasing. In a recent study from South India showed that <italic>Shigella flexneri</italic> and <italic>S. sonnei</italic> resistance to nalidixic acid was greater than 95% [<xref ref-type="bibr" rid="CR21">21</xref>]. Similarly, in a study between 2008 and 2010 assessing the <italic>Campylobacter spp.</italic> susceptibility patterns showed that 100% of the isolates were resistant to nalidixic acid and ciprofloxacin [<xref ref-type="bibr" rid="CR22">22</xref>]. Increasing quinolone resistance has resulted in the use of third generation cephalosporins (ceftriaxone and cefixime) belonging to Watch group as empiric treatment choices for enteric fever and bacterial dysentery. However, recent data indicate that <italic>S.</italic> Typhi has become susceptible to older antibiotics like amoxicillin, trimethoprim/sulfamethoxazole and chloramphenicol which belong to Access group. In a national scale study and 2014 ICMR AMR surveillance data, 95% of <italic>S</italic>. Typhi isolates in 2014 were susceptible to ampicillin, chloramphenicol and trimethoprim/sulfamethoxazole [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. These results indicate the opportunity to examine and report outcomes using older first-line antibiotics (amoxicillin, trimethoprim/sulfamethoxazole and chloramphenicol) belonging to Access group among mild and moderately severe enteric fever cases especially in centers where microbiological and antimicrobial susceptibility services are available.</p></sec><sec id="Sec3"><title>Lack of availability of narrow-spectrum antibiotics</title><p id="Par18">The use of Watch group antibiotics namely second and third generation cephalosporins is associated with widespread availability of these antibiotics. A review of the April–July 2017 edition of the Current Index of Medical Specialties (CIMS) India, showed that 135 pharmaceutical companies were manufacturing cefixime (third-generation cephalosporin), 103 were manufacturing cefpodoxime (third generation cephalosporins) and 69 were manufacturing cefuroxime (second generation cephalosporin) [<xref ref-type="bibr" rid="CR6">6</xref>]. In contrast, 112 companies were manufacturing amoxicillin-clavulanic acid, 51 were manufacturing amoxicillin and only one company was manufacturing penicillin and benzathine penicillin [<xref ref-type="bibr" rid="CR6">6</xref>]. The lack of availability of Access group antibiotics such as amoxicillin and benzathine penicillin was evident in studies focused on availability of antibiotics in public and private pharmacies. A study was conducted in New Delhi (July–October 2011) to examine the access of antibiotics at primary care, secondary care and tertiary care facilities of public health providers in Delhi and private retail pharmacies [<xref ref-type="bibr" rid="CR23">23</xref>]. The results indicated that benzathine penicillin was not available at primary care, secondary care and tertiary care facilities of public sector surveyed, whereas ampicillin suspension was available only in 25% of primary care facilities and was not available in secondary and tertiary care facilities. However, cefuroxime which is part of Delhi Government’s hospital Essential Medicine List (EML)but not for primary care, was available at 44% of primary care facilities. Cefixime which was not part of Delhi Governments’ EML was available in 22% of primary care facilities and 14% of secondary care facilities. Similar to public sector, benzathine penicillin was not available in any private retail pharmacies however amoxicillin and cefixime were available in greater than 90% of the private pharmacies [<xref ref-type="bibr" rid="CR23">23</xref>]. Interestingly, the median price ratio (MPR) of second and third generation cephalosporins belonging to Watch group is lower when compared to amoxicillin belonging to Access group in both public sector procurement agencies and private retail pharmacies [<xref ref-type="bibr" rid="CR23">23</xref>].The MPR is the local median unit price of a medicine in comparison with the median unit price of international reference price which was found in the Management Sciences for Health (MSH) Price Indicator Guide.</p></sec><sec id="Sec4" sec-type="conclusions"><title>Conclusions</title><p id="Par19">The current situation in India shows that there is excess use and availability of Watch group of antibiotics compared to Access group of antibiotics. Indian authorities should consider revising the National EML and adopt the WHO EML for antibiotics in three categories (AWaRe) to optimize the use of antimicrobials. Measures should be taken by regulators and policy makers to improve the availability and use of Access group of antibiotics and at the same time decrease the use of Watch group of antibiotics that have higher resistance potential in both public and private sector. A policy decision can be taken to ask at least public sector pharmaceutical manufacturing units to manufacture Access group of antibiotics and these antibiotics should be available at government owned ‘Generic Drug’ stores and procured for all public sectors. Standard treatment guidelines should be prepared based on current sensitivity patterns and implemented at public and private facilities so that doctors start prescribing Access group of antibiotics as first line drugs. Prescription audits at all level of healthcare and feedback to prescribers and facility manager will further improve the quality of prescribing.</p></sec></body><back><ack><title>Acknowledgements</title><sec><p>Not applicable.</p></sec><sec id="FPar2"><title>Funding</title><p id="Par21">No funding.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par22">Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></sec></ack><sec sec-type="author-contribution"><title>Authors’ contributions</title><p>SG and AK conceptualized and drafted the manuscript. Both the authors have edited and approve the submitted final MS.</p></sec><sec sec-type="ethics-statement"><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par20">Not applicable.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par23">Not applicable.</p></sec><sec id="FPar5" sec-type="COI-statement"><title>Competing interests</title><p id="Par24">The authors declare they have no competing interest.</p></sec><sec id="FPar6"><title>Publisher’s Note</title><p id="Par25">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Antimicrobial Resistance<bold>:</bold> Tackling a crisis for the health and wealth of nations<bold>,</bold> Report By Jim O' Neill, 2014.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharland</surname><given-names>M</given-names></name><name><surname>Pulcini</surname><given-names>C</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>M</given-names></name><name><surname>Gandra</surname><given-names>S</given-names></name><name><surname>Mathur</surname><given-names>S</given-names></name><name><surname>Magrini</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Classifying antibiotics in the WHO essential medicines list for optimal use—be AWaRe</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>18</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30724-7</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGettigan</surname><given-names>P</given-names></name><name><surname>Roderick</surname><given-names>P</given-names></name><name><surname>Kadam</surname><given-names>A</given-names></name><name><surname>Pollock</surname><given-names>AM</given-names></name></person-group><article-title xml:lang="en">Access, watch, and reserve antibiotics in India: challenges for WHO stewardship</article-title><source>Lancet Glob Health</source><year>2017</year><volume>5</volume><issue>11</issue><fpage>e1075</fpage><lpage>e1076</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30365-0</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, Goossens H, Laxminarayan R. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci. 2018:201717295.</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsia</surname><given-names>Y</given-names></name><name><surname>Sharland</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>IC</given-names></name><name><surname>Magrini</surname><given-names>N</given-names></name><name><surname>Bielicki</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Consumption of oral antibiotic formulations for young children according to the WHO access, watch, reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries</article-title><source>Lancet Infect Dis</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30547-4</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gandra</surname><given-names>S</given-names></name><name><surname>Joshi</surname><given-names>J</given-names></name><name><surname>Trett</surname><given-names>A</given-names></name><name><surname>Sankhil</surname><given-names>L</given-names></name></person-group><source>Scoping report on antimicrobial resistance in India</source><year>2017</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>Center for Disease Dynamics Economics &amp; Policy</publisher-name></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>DL</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name></person-group><article-title xml:lang="en">Extended-spectrum β-lactamases: a clinical update</article-title><source>Clin Microbiol Rev</source><year>2005</year><volume>18</volume><issue>4</issue><fpage>657</fpage><lpage>686</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2MXht1Wrsr%2FE</pub-id><pub-id pub-id-type="doi">10.1128/CMR.18.4.657-686.2005</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calbo</surname><given-names>E</given-names></name><name><surname>Romaní</surname><given-names>V</given-names></name><name><surname>Xercavins</surname><given-names>M</given-names></name><name><surname>Gómez</surname><given-names>L</given-names></name><name><surname>Vidal</surname><given-names>CG</given-names></name><name><surname>Quintana</surname><given-names>S</given-names></name><name><surname>Vila</surname><given-names>J</given-names></name><name><surname>Garau</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases</article-title><source>J Antimicrob Chemother</source><year>2006</year><volume>57</volume><issue>4</issue><fpage>780</fpage><lpage>783</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD28Xis1Glur0%3D</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkl035</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandra</surname><given-names>S</given-names></name><name><surname>Mojica</surname><given-names>N</given-names></name><name><surname>Klein</surname><given-names>EY</given-names></name><name><surname>Ashok</surname><given-names>A</given-names></name><name><surname>Nerurkar</surname><given-names>V</given-names></name><name><surname>Kumari</surname><given-names>M</given-names></name><name><surname>Ramesh</surname><given-names>U</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Vadwai</surname><given-names>V</given-names></name><name><surname>Das</surname><given-names>BR</given-names></name></person-group><article-title xml:lang="en">Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014</article-title><source>Int J Infect Dis</source><year>2016</year><volume>50</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.08.002</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Holloway</surname><given-names>K</given-names></name><name><surname>Chaudhury</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Methodology for surveillance of antimicrobials use among out-patients in Delhi</article-title><source>Indian J Med Res</source><year>2009</year><volume>129</volume><issue>5</issue><fpage>555</fpage><pub-id pub-id-type="pmid">19675384</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Holloway</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Trends in antibiotic use among outpatients in New Delhi, India</article-title><source>BMC Infect Dis</source><year>2011</year><volume>11</volume><issue>1</issue><fpage>99</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-11-99</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Organization WH: the selection and use of essential medicines: report of the WHO expert committee, 2017 (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children): World Health Organization; 2017.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Holloway</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Delhi, India</article-title><source>Tropical Med Int Health</source><year>2014</year><volume>19</volume><issue>7</issue><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1111/tmi.12327</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Joshi</surname><given-names>P</given-names></name><name><surname>Jhamb</surname><given-names>U</given-names></name><name><surname>Holloway</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Prescriber and dispenser perceptions about antibiotic use in acute uncomplicated childhood diarrhea and upper respiratory tract infection in New Delhi: qualitative study</article-title><source>Indian J Pharmacol</source><year>2017</year><volume>49</volume><issue>6</issue><fpage>419</fpage><pub-id pub-id-type="doi">10.4103/ijp.IJP_508_17</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Swain</surname><given-names>PK</given-names></name><name><surname>Suri</surname><given-names>J</given-names></name><name><surname>Gaur</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Antimicrobial drug prescribing patterns for community-acquired pneumonia in hospitalized patients: a retrospective pilot study from New Delhi, India</article-title><source>Indian J Pharmacol</source><year>2015</year><volume>47</volume><issue>4</issue><fpage>375</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XnsFels74%3D</pub-id><pub-id pub-id-type="doi">10.4103/0253-7613.161258</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandra</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><name><surname>Jinka</surname><given-names>DR</given-names></name><name><surname>Kanithi</surname><given-names>R</given-names></name><name><surname>Chikkappa</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Dharmapalan</surname><given-names>D</given-names></name><name><surname>Vasudevan</surname><given-names>AK</given-names></name><name><surname>Tunga</surname><given-names>O</given-names></name><name><surname>Akula</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Point prevalence surveys of antimicrobial use among hospitalized children in six hospitals in India in 2016</article-title><source>Antibiotics</source><year>2017</year><volume>6</volume><issue>3</issue><fpage>19</fpage><pub-id pub-id-type="doi">10.3390/antibiotics6030019</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torumkuney</surname><given-names>D</given-names></name><name><surname>Chaiwarith</surname><given-names>R</given-names></name><name><surname>Reechaipichitkul</surname><given-names>W</given-names></name><name><surname>Malatham</surname><given-names>K</given-names></name><name><surname>Chareonphaibul</surname><given-names>V</given-names></name><name><surname>Rodrigues</surname><given-names>C</given-names></name><name><surname>Chitins</surname><given-names>D</given-names></name><name><surname>Dias</surname><given-names>M</given-names></name><name><surname>Anandan</surname><given-names>S</given-names></name><name><surname>Kanakapura</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Results from the survey of antibiotic resistance (SOAR) 2012–14 in Thailand, India, South Korea and Singapore</article-title><source>J Antimicrob Chemother</source><year>2016</year><volume>71</volume><issue>suppl_1</issue><fpage>i3</fpage><lpage>i19</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw073</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">National Center for Disease Control. National Treatment Guidelines for antimicrobial use in Infectious Diseases; 2016.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>NK</given-names></name></person-group><article-title xml:lang="en">Rational use of antibiotics for pneumonia</article-title><source>Indian Pediatr</source><year>2010</year><volume>47</volume><issue>1</issue><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s13312-010-0015-4</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Indian Council of Medical Research. Treatment guidelines for antimicrobial use in common syndromes, 2017.</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anandan</surname><given-names>S</given-names></name><name><surname>Sethuvel</surname><given-names>DPM</given-names></name><name><surname>Gajendiren</surname><given-names>R</given-names></name><name><surname>Verghese</surname><given-names>VP</given-names></name><name><surname>Walia</surname><given-names>K</given-names></name><name><surname>Veeraraghavan</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Molecular characterization of antimicrobial resistance in clinical Shigella isolates during 2014 and 2015: trends in South India</article-title><source>Germs</source><year>2017</year><volume>7</volume><issue>3</issue><fpage>115</fpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1MXkvFaht7w%3D</pub-id><pub-id pub-id-type="doi">10.18683/germs.2017.1116</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>P</given-names></name><name><surname>Ramamurthy</surname><given-names>T</given-names></name><name><surname>Bhattacharya</surname><given-names>MK</given-names></name><name><surname>Rajendran</surname><given-names>K</given-names></name><name><surname>Mukhopadhyay</surname><given-names>AK</given-names></name></person-group><article-title xml:lang="en">Campylobacter jejuni in hospitalized patients with diarrhea, Kolkata, India</article-title><source>Emerg Infect Dis</source><year>2013</year><volume>19</volume><issue>7</issue><fpage>1155</fpage><pub-id pub-id-type="doi">10.3201/eid1907.121278</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotwani</surname><given-names>A</given-names></name><name><surname>Holloway</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Access to antibiotics in New Delhi, India: implications for antibiotic policy</article-title><source>J Pharm Policy Prac</source><year>2013</year><volume>6</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/2052-3211-6-6</pub-id></mixed-citation></ref></ref-list></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>CIMS</term><def><p id="Par1">Current index of medical specialties</p></def></def-item><def-item><term>DDD</term><def><p id="Par2">Defined daily dose</p></def></def-item><def-item><term><italic>E coli</italic></term><def><p id="Par3"><italic>Escherichia coli</italic></p></def></def-item><def-item><term>EML</term><def><p id="Par4">Essential medicine list</p></def></def-item><def-item><term>ESBL</term><def><p id="Par5">Extended spectrum beta-lactamase</p></def></def-item><def-item><term>INR</term><def><p id="Par6">Indian rupee</p></def></def-item><def-item><term>LRTIs</term><def><p id="Par7">Lower respiratory tract infections</p></def></def-item><def-item><term><italic>S. Typhi</italic></term><def><p id="Par8">Salmonella Typhi</p></def></def-item><def-item><term>URTIs</term><def><p id="Par9">Upper respiratory tract infections</p></def></def-item><def-item><term>WHO</term><def><p id="Par10">World health organization</p></def></def-item></def-list></glossary></back></article></records><facets><facet name="subject"><facet-value count="1">Drug Safety and Pharmacovigilance</facet-value><facet-value count="1">Pharmaceutical Sciences/Technology</facet-value><facet-value count="1">Pharmacoeconomics and Health Outcomes</facet-value><facet-value count="1">Pharmacology/Toxicology</facet-value><facet-value count="1">Pharmacy</facet-value></facet><facet name="keyword"/><facet name="pub"><facet-value count="1">Journal of Pharmaceutical Policy and Practice</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">India</facet-value><facet-value count="1">United States</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
